Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6620566rdf:typepubmed:Citationlld:pubmed
pubmed-article:6620566lifeskim:mentionsumls-concept:C0028773lld:lifeskim
pubmed-article:6620566lifeskim:mentionsumls-concept:C0018417lld:lifeskim
pubmed-article:6620566lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:6620566lifeskim:mentionsumls-concept:C0055000lld:lifeskim
pubmed-article:6620566lifeskim:mentionsumls-concept:C1521738lld:lifeskim
pubmed-article:6620566lifeskim:mentionsumls-concept:C0144299lld:lifeskim
pubmed-article:6620566pubmed:issue5lld:pubmed
pubmed-article:6620566pubmed:dateCreated1983-11-23lld:pubmed
pubmed-article:6620566pubmed:abstractTextT-1982 (cefbuperazone) concentrations in antecubital venous blood and pelvic dead space exudate were examined in 4 patients who had received radical hysterectomy due to uterocervical cancer. Data analysis for the transfer of T-1982 into pelvic dead space exudate was performed with the stimulation curves prepared from pharmacokinetic parameters by the three-compartment model. When T-1982 was given at a dose of 1 g, the peak level in the venous blood was 83.7 micrograms/ml at 1 hour after the start of administration. With regards to T-1982 concentration in pelvic dead space exudate, the peak level of 19.3 micrograms/ml was observed at 2.24 hours after the start of administration and relatively high concentration of about 6.1 micrograms/ml was observed even at 8 hours after the start of administration. From the above results, it is concluded that T-1982 is a useful drug for the treatment of infections in the field of obstetrics and gynecology.lld:pubmed
pubmed-article:6620566pubmed:languagejpnlld:pubmed
pubmed-article:6620566pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620566pubmed:citationSubsetIMlld:pubmed
pubmed-article:6620566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620566pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6620566pubmed:statusMEDLINElld:pubmed
pubmed-article:6620566pubmed:monthMaylld:pubmed
pubmed-article:6620566pubmed:issn0368-2781lld:pubmed
pubmed-article:6620566pubmed:authorpubmed-author:KondoHHlld:pubmed
pubmed-article:6620566pubmed:authorpubmed-author:IwasaSSlld:pubmed
pubmed-article:6620566pubmed:authorpubmed-author:ItohKKlld:pubmed
pubmed-article:6620566pubmed:authorpubmed-author:NodaKKlld:pubmed
pubmed-article:6620566pubmed:authorpubmed-author:HayasakaEElld:pubmed
pubmed-article:6620566pubmed:issnTypePrintlld:pubmed
pubmed-article:6620566pubmed:volume36lld:pubmed
pubmed-article:6620566pubmed:ownerNLMlld:pubmed
pubmed-article:6620566pubmed:authorsCompleteYlld:pubmed
pubmed-article:6620566pubmed:pagination982-5lld:pubmed
pubmed-article:6620566pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:meshHeadingpubmed-meshheading:6620566-...lld:pubmed
pubmed-article:6620566pubmed:year1983lld:pubmed
pubmed-article:6620566pubmed:articleTitle[A fundamental study on T-1982 (cefbuperazone) in the field of obstetrics a gynecology].lld:pubmed
pubmed-article:6620566pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6620566pubmed:publicationTypeEnglish Abstractlld:pubmed